Latest news

• BMS' Opdivo backed as melanoma therapy in EU

  FDA approval as a second-line non-small cell lung cancer (NSCLC) therapy - a much larger market opportunity - in March. ... Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally

• Running medical meetings

  The sensitivities of the 'world' sector manifest in secretive meetings, 24-hour emails, decisions and non-decisions, last minute changes and demands, security focus, approvals… and the list goes on.

• FDA approves sleep disorder drug for blind people

  Vanda Pharmaceuticals is now allowed to market its drug Hetlioz (tasimelteon) to treat a condition called non-24-hour sleep-wake disorder, which causes problems in the sleep cycle of blind ... Non-24 affects people who are completely blind as light does

• FDA panel backs sleep pattern drug for blind

  A Food Drug and Administration (FDA) advisory committee voted unanimously to recommend approval of Vanda Pharmaceuticals' Hetlioz (tasimelteon) for non-24-hour disorder (N24) in the totally blind. ... As a result, they can "fully enjoy the opportunities

• Study suggests bias in industry research

  A new study in Annals of Internal Medicine suggests that drug studies funded by industry are significantly more likely to have favourable outcomes than those funded by the government or ... About 56 per cent of the trials funded by non-profits were